BioAtla Statistics
Total Valuation
BioAtla has a market cap or net worth of $7.12 million. The enterprise value is $6.55 million.
Important Dates
The next estimated earnings date is Friday, May 8, 2026, after market close.
| Earnings Date | May 8, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BioAtla has 1.66 million shares outstanding. The number of shares has increased by 21.11% in one year.
| Current Share Class | 1.66M |
| Shares Outstanding | 1.66M |
| Shares Change (YoY) | +21.11% |
| Shares Change (QoQ) | +1.79% |
| Owned by Insiders (%) | 7.30% |
| Owned by Institutions (%) | 11.01% |
| Float | 1.38M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.74 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.28 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.37
| Current Ratio | 0.37 |
| Quick Ratio | 0.32 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -110.76% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 725.29% |
| Weighted Average Cost of Capital (WACC) | 5.95% |
| Revenue Per Employee | $48,780 |
| Profits Per Employee | -$1.45M |
| Employee Count | 41 |
| Asset Turnover | 0.06 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -79.66% in the last 52 weeks. The beta is 1.21, so BioAtla's price volatility has been higher than the market average.
| Beta (5Y) | 1.21 |
| 52-Week Price Change | -79.66% |
| 50-Day Moving Average | 7.31 |
| 200-Day Moving Average | 23.21 |
| Relative Strength Index (RSI) | 36.32 |
| Average Volume (20 Days) | 56,063 |
Short Selling Information
The latest short interest is 113,264, so 6.84% of the outstanding shares have been sold short.
| Short Interest | 113,264 |
| Short Previous Month | 2.37M |
| Short % of Shares Out | 6.84% |
| Short % of Float | 8.19% |
| Short Ratio (days to cover) | 2.48 |
Income Statement
In the last 12 months, BioAtla had revenue of $2.00 million and -$59.61 million in losses. Loss per share was -$50.66.
| Revenue | 2.00M |
| Gross Profit | -41.07M |
| Operating Income | -58.71M |
| Pretax Income | -59.61M |
| Net Income | -59.61M |
| EBITDA | -58.33M |
| EBIT | -58.71M |
| Loss Per Share | -$50.66 |
Full Income StatementBalance Sheet
The company has $7.12 million in cash and $6.20 million in debt, giving a net cash position of $918,000 or $0.55 per share.
| Cash & Cash Equivalents | 7.12M |
| Total Debt | 6.20M |
| Net Cash | 918,000 |
| Net Cash Per Share | $0.55 |
| Equity (Book Value) | -36.19M |
| Book Value Per Share | -28.51 |
| Working Capital | -13.91M |
Full Balance SheetCash Flow
| Operating Cash Flow | -48.20M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 373,000 |
| Net Borrowing | 7.13M |
| Free Cash Flow | -48.20M |
| FCF Per Share | -$29.09 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -2,935.25% |
| Pretax Margin | -2,980.35% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |